Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Jake Freeman Is A Genius
youtu.be/XKLzY3LAXxs
.21 pre consolidation...lol..next stop is 2.50 = .16....blind leading the blind...sad so sad...
Barrow Debate Letter
mindmed.zone/barrow-letter
M$
I thought George Economou was the most ruthless CEO bastard, especially when he stood outside the NASDAQ bldg few years ago, and was quoted as saying "US Investors are stupid people"....
Brutal Just Brutal
Basically a double whammy w/ reverse split.
really screwed over minority SH
Breaking News - O’Leary is a Clueless F**kwad
Take it from someone who is in the industry, O’Leary oozed his way on to Shark Tank as a nobody who got lucky with a hit show and has parlayed that fame into a psuedo-successful personality. He was a relative nobody prior to Shark Tank and since has become a household name, using that recognition to release a bunch of financial nonsense including some underperforming index funds, half-assed “brands” and recommendations that carry weight for those foolish enough to think he has cared because he’s on TV.
Basically, O’Leary is a Kardashian with half the money and following but none of the hair. Although he may s*CK a mean D like a Kardasian…..
MindMed Board is Trippin': Significant Investor Calls for Termination of Highly Dilutive Equity Offering and Pledges to Hold Board and Management Accountable through Activist Campaign
3:52 pm ET September 28, 2022 (PR Newswire)
Investors States Shareholder Requisition of Special Meeting to Effect Significant Change to the Board May be Necessary
Today, FCM MM HOLDINGS, LLC ("FCM") announces that it has sent a letter (the "Letter") to the Board of Directors (the "Board") of Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) ("MindMed" or the "Company") informing the Board of FCM's vehement opposition to the Company's public offering announced on September 27, 2022 (the "Dilutive Offering"). In the Letter, FCM details how the Board's and management's actions, including the Dilutive Offering, have destroyed shareholder value, calls for the Board to immediately terminate the offering, and pledges to take action to hold the Board accountable.
"We are committed to taking whatever actions are necessary to protect the interest of shareholders"
"We are committed to taking whatever actions are necessary to protect the interest of shareholders, and we look forward to engaging in a zealous proxy campaign" said FCM Chief Executive Manager Jake Freeman.
The full text of the letter is available and can be downloaded at mindmed.zone/letterdilution
About FCM
FCM is managed by Jake Freeman and represents an investment of 6.1% of MindMed's shares outstanding.
FCM additionally represents other early investors in MindMed, including Scott Freeman and Chad Boulanger, who all have a strong interest in seeing the long-term success of MindMed.
For additional disclosure relating to public broadcast solicitations please see mindmed.zone/disclosure
Media ContactJake FreemanChief Executive ManagerFCM MM HOLDINGS, LLC30 N Gould St. Ste RSheridan, WY 82801Phone: 908-308-2381Email: jake@mindmed.zone
https://c212.net/c/img/favicon.png?sn=NY87372&sd=2022-09-28
View original content:https://www.prnewswire.com/news-releases/mindmed-board-is-trippin-significant-investor-calls-for-termination-of-highly-dilutive-equity-offering-and-pledges-to-hold-board-and-management-accountable-through-activist-campaign-301636059.html
SOURCE FCM MM Holdings, LLC
https://rt.prnewswire.com/rt.gif?NewsItemId=NY87372&Transmission_Id=202209281551PR_NEWS_USPR_____NY87372&DateId=20220928
MindMed’s “leadership” strike me as a bunch of clueless cuntz in some key areas. I still hold my shares as I believe in the space and the mission however, you can bet on the best horse but still be stuck with the worst Jockey. In a pickle. Time will tell.
So that’s why. More dilution!
Good grief. Another stock offering. But at $4.25?
Who buys?
GLTA
It was in my watch list. I screen those and follow. Saw the drop premarket, read the reason why, and bought it.
Maybe there is a more precise cash or mkt cap figure as I am just going off of yahoo, but either way, it's pretty close. Today's candle fell off the chart...
https://finance.yahoo.com/quote/MNMD?p=MNMD
https://schrts.co/VXRZaHvG
Currently, I believe the company's market cap is now less than it's cash on hand. Are you using any valuation method to determine your entry here? Or just the extremity of the drop and the chart?
Made many attempts to find out for certain however to no avail so far.
Been waiting to buy this. Appreciate the starter ;)
Sold this pig last week, when it couldn't hold 6.
Is O'Leary's position not posted?
CEO Robert Barrow needs to step down. Kevin O'Leary needs to speak up and share with us the status of his investment in MindMed. The term "All the gear but no f#cking idea" applies to the current MindMed leadership and PR team.
Don’t worry everyone… in a couple of more weeks we can just do another one of those reverse splits again… ha ha ha lol
Maybe we should do a 30-1 this time…
I'm sure others are getting beat up on this, but for me it's a gift and I took it. GLTA
Really bad share structure decisions by management, and a perfect storm of market conditions spurred by Covid, inflation, energy shortages and a war in eastern Europe. Pretty sad. Looks like stop losses are getting triggered left and right by the people stupid enough to use them.
lol...2 99 = .19 blew right by 3 so l see a 2.25 close = .15...lol...sad so very, very sad...
Terrible for longs but a gem for shorts! As longvas there is shorting allowed by the sec, this is always going to happen
A lead balloon couldn’t fall this fast!
What is going on!
GLTA
Shareholder raping event is what I called it many years now. SEC needs to halt this sort of abuse by the Insiders of a corp to its Shareholders; and eliminate/curtail shorting events like this. OR, simply put, and in this economy going forward reminiscent of late 1970's, NOBODY will be investing in US equity markets again and then everything will collapse so volatile the even the shortsellers will be hurt by implemented new tax rules and costs upon them..
Don't think can happen. Just watch all you youngins' out there.
I have lived this sh!t scenario before over 400 years ago and we are heading there again under Biden Admin and today's Democrat (Marxist) Party...
On a positive, SEC just found a bunch of Wall Street investment firms/brokers guilty of private deals on I-Phones to certain clients ad fined them $1.8 Billion...
Lets give it to the longs, have a RS, then we’l have an offering after that, what a nightmare for longs but a dream come true for shorts $$$
Omg, longs got shafted! Wow! Told everyone to short this, we made our wealth here rather easily an in 2.5 weeks! Omg $$$$
Putin couldn’t mess things up this bad!
Good grief
Tried warning you...hows your .26 presplit....sad so sad...they blew right by 5.15 to 3.99...lol...say hello to 3.29 tomorrow...what a scam....
Short short short makes wealth with these useless tickers
Not looking so hot here. The presplit adjusted price is around .38. Hope all that wanted out cashed out in that spike before the RS.
$5.15 just flashed....another ugly red day coming...sad so sad....say hello to $4.38 (.29l by Friday...sad so sad....
At least it is spreading locally. Which we knew. There are many other sites yet that we do not know about. Should start to get some good coverage.
Bad news....l just saw a 5.47 flash...sad so sad...a little more shorting yet to be done...
Boom, right on par, fell below 6 area! Its basically now a bit below the pre split price if u times the split ration at pre split price area. Probably will seek 5 before more short positions are covered, loads of wealth were made here
Good info! I submitted for info on the trials since I am local.
$MNMD - Miami clinic kicks off first national study of LSD, once a ‘public enemy,’ to treat anxiety
https://www.miamiherald.com/news/health-care/article266041696.html
BY NATALIA GALICZA UPDATED SEPTEMBER 22, 2022 5:52 PM Patients who participate in the MM-120 study at Segal Trials’ Center for Psychedelic and Cannabis Research in Miami Lakes will be dosed and observed in a room made to resemble more of a home than a sterile clinic. SEGAL TRIALS Courtesy of The gurus of the psychedelic era of American pop culture extolled the experience of the “acid trip.” But the U.S. government and much of the public remained leery of LSD, with President Nixon declaring it and assorted other drugs “public enemy No. 1.” Now, half a century after Nixon launched the War on Drugs, a Miami-area private research clinic has kicked off a federally approved clinical trial to test LSD as a possible treatment for generalized anxiety disorder. The milestone trial — billed by the drug developer as the largest study of LSD for potential commercial use ever conducted in the United States — reflects a growing body of research that suggests those hippies were maybe on to something: That the mind-altering power of LSD, mushrooms and a host of other hallucinogens — if administered in controlled amounts under medical supervision — might have some beneficial properties, particularly in treating psychological problems. TOP VIDEOS × The inaugural dose of the latest trial was administered to a patient on Aug. 24 by Segal Trials, at its Center for Psychedelic and Cannabis Research in Miami Lakes. The proprietary “pharmaceutically optimized“ form of LSD is named MM-120 and owned by MindMed, a small psychedelic biotechnology company based in New York. MindMed’s study could be a significant step in the long process of potentially bringing a new treatment for generalized anxiety disorder to the market. The study spans 20 clinics nationwide, including Segal Trials. Get unlimited digital access Subscribe now for just $2 for 2 months. CLAIM OFFER MIAMI A PERFECT TEST SITE Rishi Kakar, medical director and chief scientific officer at Segal, said Miami-Dade’s large population and diverse demographic make the county a perfect site for the medical trial. “There are more patients here who have anxiety and don’t have enough access to treatment, or the treatment is not meeting their goals,” he said. “We as a geography are uniquely positioned for that in Miami. We have a breadth of diverse patient populations.” The study, kicking off a second phase, is designed to monitor both the drug’s effects and to find the most effective dosage. Patients will receive one of four different dose strengths while others will get a placebo. Segal Trials will likely contribute 10 to 20 patients out of the 200 MindMed is testing in this second phase. Patients who receive doses will be monitored in a room designed to feel more like home than a sterilized clinic. The first patient in Miami Lakes, Kakar said, reclined on a couch while under the influence of the drug — headset, eye mask and blanket provided. Two guides with experience overseeing psychedelic-assisted psychotherapy monitored the patient for the entire duration of its psychoactive effects, which Kakar estimated to be about 12 hours. Psychedelics — like LSD or “acid”, Psilocybin or “magic mushrooms,” among others — are not new, not in a recreational nor a therapeutic context. The psychoactive drugs were widely studied and administered to curb alcohol addiction, post-traumatic stress disorder, anxiety and depression in the United States until they became criminalized in 1968. Now, after steadily increasing community demand, they’re reentering psychiatric research in a big way. Illegal forms of LSD are often sold in sheets of tabs like this wound found by police during a raid several years of a suspected drug dealer’s home in Northwest Miami-Dade. Courtesy of the Miami-Dade State Attorney’s Office The past decade has been fruitful for research. Promising studies on Psilocybin as a treatment for anxiety, depression and addiction have multiplied alongside research into MDMA (Methylenedioxymethamphetamine) — “club drugs” more commonly called ecstasy or molly — as a potential treatment for post-traumatic stress disorder and addiction. LSD was also widely studied, though mostly before the 1968 ban. The National Institutes of Health funded more than a hundred grants for the drug’s study prior to its prohibition. Some of those studies also found use for the compound in quelling anxiety and addiction. Bill Wilson, founder of Alcoholics Anonymous, famously credits LSD for helping him on his road to sobriety. RENEWED RESEARCH, COMMERCIAL INTEREST Those studies and breakthroughs ran largely dry following the ban. But studies like MindMed’s are sparking renewed interest in LSD, and a broad umbrella of possible psychedelic treatments. Joseph Lichter, a chemist who teaches a “Psychedelic Renaissance” course at Florida International University’s honors college, believes that such research could prove promising for the future of American psychiatry. The mind-altering substances have been feared or considered dangerous for decades, but are powerful non-toxic compounds that have captivated scientists and researchers since long before they were outlawed. “We definitely need to see more science before we start putting these things into healthcare professionals’ hands to use with clients, but it’s really a good thing for us to work toward destigmatizing LSD,” Lichter said. He believes there’s no better place to kick start a psychedelic renaissance — a resurgence of research on the taboo substances — than Miami-Dade County. “Anytime something is happening here in Miami-Dade County, I’m excited by it because we’re a big metropolis,” Lichter said. “I think the psychedelic renaissance right now is in a research-heavy period, and things like the trials at Segal are the correct steps forward.” Clinics offering Ketamine, a psychoactive sedative, already exist across the county. Psilocybin has also gained medical traction; Segal Trials conducted its own trials of Psilocybin-assisted psychotherapy for treatment of depression at its Miami Lakes center last summer. “There is such a renewed interest, there is such a large unmet need in our community in that particular area,” Kakar said. “And psychedelics look like they are getting more normalized in the minds of patients and communities versus being on the fringes of recreational use.” LONGER LASTING EFFECTS What sets MM-120 and other psychedelic treatments apart from more traditionally prescribed treatments for anxiety and depression is the length of effect. Rather than daily use, the drug candidate is being studied as a one-time treatment that promises — at least potentially — lasting benefits. “Unlike current medications that have to be taken on a daily basis for a very long time and hopefully have a realized effect many weeks down the line, we believe if this medication is taken once under structured conditions, it can have a potential effect on anxiety that lasts for a very long time,” Kakar said. “So we believe it works in a very different way pharmacologically than any other drug that has to be taken on a daily basis.” Robert Barrow, CEO of MindMed, has touted the potential in company press releases, pointing to one recent research paper from a partner in the MM-120 study.
MindMed, he wrote, is working with the University Hospital of Basel, Switzerland, which is the world’s top research center for LSD in medical applications. Earlier this month, the University Hospital of Basel published a paper with results from its own study on how well LSD curbs anxiety. “This paper further reinforces the positive preliminary evidence for LSD in patients who suffer from anxiety disorders,” Barrow said. “Acute administration of LSD produced long-lasting and notable reductions of anxiety and co-morbid depression symptoms for up to 16 weeks. These results are encouraging ....” It’s unclear how long the second phase of the trial will last. Once there is enough data across all participating sites, MindMed will approve a specific dose of MM-120 to be studied in phase three. The third and final phase will test a larger pool of patients with only the approved dose. It will be the last step before MindMed can submit the drug to the Food and Drug Administration for approval and possible future prescription usage. The company estimates the entire process will be complete by November of next year, but that could be subject to change if the phases drag on longer than expected. But despite the promising research, LSD still arguably gets the worst rap out of all the psychedelics. The drug has a tarnished reputation for being associated with counterculture, anti-war protests and “bad trips.” It’s powerful even in small amounts and, when taken in too high a dose or in an unstructured environment, can cause extreme stress or unsafe conditions for the user. The stigma attached to LSD is why Lichter teaches his students a phrase coined by Humphrey Osmond, a British psychiatrist who coined the word psychedelic. “‘To fathom hell or go angelic, just take a pinch of psychedelic’ is the phrase Osmond came up with,” Lichter said. “There’s a risk of going into a hellish place with this compound or a potential to go into an angelic place. We all have to have that recognition that there is a huge risk.” But, he said, there is a lot of room in between those extremes and the potential benefits are too enticing for some scientists not to support. “In reality it’s just a chemical compound that binds to a serotonin receptor and causes changes to the way people think or feel,” Lichter said. “And if that change can actually help them, which is what some of these studies are showing, we need to destigmatize it and give it hope, give it the attention it deserves.” This story was originally published September 22, 2022 5:30 AM.
Read more at: https://www.miamiherald.com/news/health-care/article266041696.html#storylink=cpy
.40 @ 15 split ratio is probably gonna hold the value around that, 6$ area maybe 5.25/5.50 area whales may load, we’l c where she goes, might take a long position since we covered $$$$$
Listen pal, we posted to say our opinion, an 98.5% of the time we are correct! Sorry if you can’t understand a stock play when its right in front of you for taking
Lmao, told everyone this would be a wealth maker an it was, extreme 6 digit profit on a short position, thank you to the management team running this sh..show! $$$$
If they would have dropped the ATM program like myself and FCM had suggested, their RS wouldn't have been so brutal. They would have had much more stability afterward. I called for .32, which was book value before the dumping. Today, at $5.8, is about .38, so we are not far from there. However, book value is now at $4.38, or ~.29.
$5.70 just flashed my peeps....not looking good at all...new lows every hour....lol.....
Just saw a 6.05 flash....OMG could end up in the 5 80 range by week end...sad so sad....that's only 4 dollars.from another RS...lol
and the bleeding continues
again, these reverse splits rarely end well for minority SH
Nosnibor, FIRST, is the SEC needs to address shortselling schemes that go on from supposed ethical licensed industry players.. Just like banking industry, MOST are the real criminals and the little people all get hurt in the end always...
And this was upgraded 2 days ago to $75.00 PPS !!!??? What a joke. Everything like I said many times before. Personal ATM for the Insiders...
They never worry about inflation or what most average people have to deal with daily out here... THEY live off of your hard earned monies and become wealthier in the process..
Here's the 6.50 flashed earlier today...now lets see if we.hit 6.25 that was flashed too...
OMG....someone just flashed 6.25...a new low, low, low coming today...sad so sad...lol
6.55 is flashing for sale and is on the table today....what joke these clowns are...we will see 6.05 by day end...sad so sad...
Followers
|
194
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
9385
|
Created
|
02/18/20
|
Type
|
Free
|
Moderators MomsSpaghetti Savannah-Marc |
Location: New York, NY / Toronto, Ontario
Flagship Products: LSD, 18-MC and other psychedelics
Treatment Focus: Addiction, ADHD, Anxiety, Depression, Headaches
Ticker: $MNMD (NASDAQ), $MMED (NEO), $MMQ (DAX),
Financial Reports: Link
SEC Filings: Link
SEDAR Filings: Link
IN THE MEDIA
”Could the Embrace of Psychedelics Lead to a Mental-Health Revolution?”, Vogue
”Psychedelics-Drug Startup Raises $24 Million Ahead of IPO”, Wall Street Journal
”Silicon Valley’s psychedelic wonder drug is almost here”, Fast Company
”Psychedelic drug company MindMed applies for nasdaq up-listing”, Forbes
”Psychedelic drugs may transform mental health care. And big business is ready to profit from the revolution”, Fortune
”A startup that wants to use psychedelics to treat addiction just raised $6.2 million from the host of Shark Tank and the architect behind the world’s biggest cannabis grower”, Business Insider
”New York is getting its first psychedelic-medicine center, with the help of a startup called MindMed, which develops hallucinogens to treat mental illness and addiction, and is funding an institute at N.Y.U. Langone Medical Center”, The New Yorker
”MindMed surges, putting it at the forefront of psychedelic euphoria”, Bloomberg
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |